LitCovid-sample-Enju  

PMC:7253482 / 18-400 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T2 1-12 NN denotes coronavirus
T3 13-19 NN denotes glycan
T4 20-27 NNS denotes shields
T5 28-35 IN denotes despite
T6 36-45 JJ denotes extensive
T7 46-59 NN denotes glycosylation
T8 61-69 NN denotes Abstract
T9 70-76 JJ denotes Severe
T10 77-82 JJ denotes acute
T11 83-94 JJ denotes respiratory
T12 95-103 NN denotes syndrome
T13 104-105 -LRB- denotes (
T14 105-109 NN denotes SARS
T15 109-110 -RRB- denotes )
T16 111-114 CC denotes and
T17 115-121 NNP denotes Middle
T18 122-126 NNP denotes East
T19 127-138 JJ denotes respiratory
T20 139-147 NN denotes syndrome
T21 148-149 -LRB- denotes (
T22 149-153 NNS denotes MERS
T23 153-154 -RRB- denotes )
T24 155-168 NNS denotes coronaviruses
T25 169-170 -LRB- denotes (
T26 170-174 NNS denotes CoVs
T27 174-175 -RRB- denotes )
T28 176-179 VBP denotes are
T29 180-188 JJ denotes zoonotic
T30 189-198 NNS denotes pathogens
T31 199-203 IN denotes with
T32 204-208 JJ denotes high
T33 209-217 NN denotes fatality
T34 218-223 NNS denotes rates
T35 224-227 CC denotes and
T36 228-236 JJ denotes pandemic
T37 237-246 NN denotes potential
T38 248-255 NN denotes Vaccine
T39 256-267 NN denotes development
T40 268-275 VBZ denotes focuses
T41 276-278 IN denotes on
T42 279-282 DT denotes the
T43 283-292 JJ denotes principal
T44 293-299 NN denotes target
T45 300-302 IN denotes of
T46 303-306 DT denotes the
T47 307-319 VBG denotes neutralizing
T48 320-327 JJ denotes humoral
T49 328-334 JJ denotes immune
T50 335-343 NN denotes response
T51 343-344 -COMMA- denotes ,
T52 345-348 DT denotes the
T53 349-354 NN denotes spike
T54 355-356 -LRB- denotes (
T55 356-357 NN denotes S
T56 357-358 -RRB- denotes )
T57 359-371 NN denotes glycoprotein
R10 T12 T13 arg1Of syndrome,(
R11 T14 T13 arg2Of SARS,(
R12 T15 T13 arg3Of ),(
R13 T12 T16 arg1Of syndrome,and
R14 T20 T16 arg2Of syndrome,and
R15 T18 T17 arg1Of East,Middle
R16 T20 T18 arg1Of syndrome,East
R17 T20 T19 arg1Of syndrome,respiratory
R18 T20 T21 arg1Of syndrome,(
R19 T22 T21 arg2Of MERS,(
R2 T4 T2 arg1Of shields,coronavirus
R20 T23 T21 arg3Of ),(
R21 T28 T24 arg1Of are,coronaviruses
R22 T24 T25 arg1Of coronaviruses,(
R23 T26 T25 arg2Of CoVs,(
R24 T27 T25 arg3Of ),(
R25 T16 T28 arg1Of and,are
R26 T30 T28 arg2Of pathogens,are
R27 T30 T29 arg1Of pathogens,zoonotic
R28 T30 T31 arg1Of pathogens,with
R29 T35 T31 arg2Of and,with
R3 T4 T3 arg1Of shields,glycan
R30 T34 T32 arg1Of rates,high
R31 T34 T33 arg1Of rates,fatality
R32 T34 T35 arg1Of rates,and
R33 T37 T35 arg2Of potential,and
R34 T37 T36 arg1Of potential,pandemic
R35 T39 T38 arg1Of development,Vaccine
R36 T39 T40 arg1Of development,focuses
R37 T40 T41 arg1Of focuses,on
R38 T44 T41 arg2Of target,on
R39 T44 T42 arg1Of target,the
R40 T44 T43 arg1Of target,principal
R41 T44 T45 arg1Of target,of
R42 T50 T45 arg2Of response,of
R43 T50 T46 arg1Of response,the
R44 T50 T47 arg1Of response,neutralizing
R45 T50 T48 arg1Of response,humoral
R46 T50 T49 arg1Of response,immune
R47 T50 T51 arg1Of response,","
R48 T57 T51 arg2Of glycoprotein,","
R49 T57 T52 arg1Of glycoprotein,the
R5 T7 T5 arg2Of glycosylation,despite
R50 T57 T53 arg1Of glycoprotein,spike
R51 T53 T54 arg1Of spike,(
R52 T55 T54 arg2Of S,(
R53 T56 T54 arg3Of ),(
R6 T7 T6 arg1Of glycosylation,extensive
R7 T12 T9 arg1Of syndrome,Severe
R8 T12 T10 arg1Of syndrome,acute
R9 T12 T11 arg1Of syndrome,respiratory